GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » EBIT per Share

Apollomics (Apollomics) EBIT per Share : $-2.80 (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Apollomics EBIT per Share?

Apollomics's EBIT per Share for the six months ended in Dec. 2023 was $-0.24. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.80.

During the past 3 years, the average EBIT per Share Growth Rate was -15.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Apollomics's EBIT per Share or its related term are showing as below:

APLMW' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -15.9   Med: -15.9   Max: -15.9
Current: -15.9

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Apollomics was -15.90% per year. The lowest was -15.90% per year. And the median was -15.90% per year.

APLMW's 3-Year EBIT Growth Rate is ranked worse than
71.63% of 1304 companies
in the Biotechnology industry
Industry Median: 3.6 vs APLMW: -15.90

Apollomics's EBIT for the six months ended in Dec. 2023 was $-21.82 Mil.

Apollomics EBIT per Share Historical Data

The historical data trend for Apollomics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics EBIT per Share Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBIT per Share
-0.86 -1.09 -2.77 -1.99

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT per Share Get a 7-Day Free Trial -0.33 -0.04 -2.74 -2.55 -0.24

Apollomics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Apollomics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-172.441/86.7958
=-1.99

Apollomics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

EBIT per Share(Q: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-21.817/89.4808
=-0.24

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-2.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics  (NAS:APLMW) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Apollomics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Apollomics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollomics (Apollomics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » EBIT per Share
Comparable Companies
ATHA STTK ACXP CARA TLSA ORMP IMMX CCCC GTHX GBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
APLM:USA
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Website
https://www.apollomicsinc.com
Apollomics Inc is an innovative clinical-stage biotechnology company. It is is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. It has a pipeline of 9 drug candidates across multiple programs, 6 of which are in the clinical stage of development.